[1]王浩凌,李冬琼,吴 旭,等.布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响[J].医学信息,2023,36(06):143-146.[doi:10.3969/j.issn.1006-1959.2023.06.031]
　WANG Hao-ling,LI Dong-qiong,WU Xu,et al.Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels[J].Journal of Medical Information,2023,36(06):143-146.[doi:10.3969/j.issn.1006-1959.2023.06.031]
点击复制

布地奈德联合噻托溴铵治疗慢阻肺的效果及对CRP、SaO2、pH水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年06期
页码:
143-146
栏目:
论著
出版日期:
2023-03-15

文章信息/Info

Title:
Effect of Budesonide Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO2 and pH Levels
文章编号:
1006-1959（2023）06-0143-04
作者:
王浩凌; 李冬琼; 吴 旭; 等
（西昌市人民医院呼吸与危重症医学科，四川 西昌 615000）
Author(s):
WANG Hao-ling; LI Dong-qiong; WU Xu; et al.
(Department of Respiratory and Critical Care Medicine,Xichang People’s Hospital,Xichang 615000,Sichuan,China)
关键词:
慢阻肺; 布地奈德福莫特罗; 噻托溴铵; C-反应蛋白; 血氧饱和度
Keywords:
Chronic obstructive pulmonary disease; Budesonide formoterol; Tiotropium bromide; C-reactive protein; Blood oxygen saturation
分类号:
R562
DOI:
10.3969/j.issn.1006-1959.2023.06.031
文献标志码:
A
摘要:
目的 探究布地奈德福莫特罗（BD/FM）联合噻托溴铵吸入剂治疗慢阻肺（COPD）的临床疗效及对C-反应蛋白（CRP）、血氧饱和度（SaO2）、pH水平的影响。方法 选择2019年3月-2022年1月西昌市人民医院收治的68例COPD患者为研究对象，采用随机数字表法分为对照组（n=34）与观察组（n=34）。对照组行BD/FM吸入治疗，观察组采用BD/FM联合噻托溴铵吸入剂治疗，比较两组临床疗效、肺功能 [用力肺活量（FVC）、1 s用力呼气容积（FEV1）、1 s用力呼气容积百分比（FEV1%）]、血气指标[SaO2、动脉血二氧化碳分压（PaCO2）、pH值]、炎性指标[CRP、白细胞介素-6（IL-6）]、症状改善情况[COPD患者自我评估测（CAT）评分、圣乔治呼吸问卷（SGRQ）评分]。结果 观察组总有效率高于对照组（P＜0.05）；观察组治疗后FVC、FEV1、FEV1%高于对照组（P＜0.05）；观察组治疗后SaO2、pH高于对照组，PaCO2低于对照组（P＜0.05）；观察组治疗后CRP、IL-6水平低于对照组（P＜0.05）；观察组CAT、SGRQ评分低于对照组（P＜0.05）。结论 BD/FM联合噻托溴铵吸入剂治疗COPD效果肯定，可改善患者肺功能，提升SaO2、pH水平，降低CRP水平，缓解临床症状，值得临床应用。
Abstract:
Objective To investigate the clinical efficacy of budesonide formoterol (BD/FM) combined with tiotropium bromide inhalation in the treatment of chronic obstructive pulmonary disease (COPD) and its effects on C-reactive protein (CRP), oxygen saturation (SaO2) and pH.Methods A total of 68 patients with COPD admitted to Xichang People’s Hospital from March 2019 to January 2022 were selected as the research objects. They were divided into control group (n=34) and observation group (n=34) by random number table method. The control group was treated with BD/FM inhalation, and the observation group was treated with BD/FM combined with tiotropium bromide inhalation. The clinical efficacy, lung function [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), percentage of forced expiratory volume in one second (FEV1%)], blood gas analysis [SaO2, arterial partial pressure of carbon dioxide (PaCO2), pH value], inflammatory indexes [CRP, interleukin-6 (IL-6)], symptom improvement [COPD patients self-assessment test (CAT) score, St. George’s respiratory questionnaire (SGRQ) score ] were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, FVC, FEV1 and FEV1% in the observation group were higher than those in the control group (P<0.05). After treatment, SaO2 and pH in the observation group were higher than those in the control group, and PaCO2 was lower than that in the control group (P<0.05). After treatment, the levels of CRP and IL-6 in the observation group were lower than those in the control group (P<0.05). The scores of CAT and SGRQ in the observation group were lower than those in the control group (P<0.05).Conclusion BD/FM combined with tiotropium bromide inhalation is effective in the treatment of COPD, which can improve lung function and blood oxygen status, increase SaO2 and pH levels, reduce CRP levels, and relieve clinical symptoms. It is worthy of clinical application.

参考文献/References:

[1]孙印,何士杰,韦海燕,等.布地奈德福莫特罗对慢性阻塞性肺疾病稳定期D组患者血清IL-17、IL-21、TLR4、m MRC分级及CAT评分的影响[J].临床内科杂志,2021,38(9):616-618.[2]王宁,栗娜,韩巧玲,等.布地奈德福莫特罗联合噻托溴铵治疗哮喘-慢性阻塞性肺疾病重叠的临床研究[J].中国综合临床,2021,37(1):39-45.[3]赵洪达,许群,刘澄英.噻托溴铵孟鲁司特钠与布地奈德福莫特罗吸入剂联合治疗对老年慢性阻塞性肺疾病患者临床疗效及血清降钙素原和高敏C反应蛋白的影响[J].山西医药杂志,2017,46(21):2638-2640.[4]薛佩妮,冯敏娟,王惠琴.噻托溴铵粉联合糖皮质激素治疗慢性阻塞性肺疾病疗效及对患者生活质量评分的影响[J].陕西医学杂志,2020,49(2):216-219.[5]Keating GM.Budesonide/formoterol Easyhaler:a guide to its use in asthma and chronic obstructive pulmonary disease[J].Drugs & Therapy Perspectives,2017,33(3):95-101.[6]胡姗姗,田凡清,杨贵丽,等.布地奈德福莫特罗粉吸入剂联合噻托溴铵喷雾剂对COPD急性加重期患者肺功能及血清MMP-9、TIMP-1水平的影响[J].中国地方病防治杂志,2019,34(4):452,454.[7]中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.[8]秦茵茵,高国英,谢晓鸿,等.噻托溴铵对慢性阻塞性肺疾病患者呼吸中枢驱动影响的临床研究[J].中国实用内科杂志,2018,38(11):1086-1089.[9]刘苔,黄海霞,杜卫祺,等.噻托溴铵辅助治疗对COPD急性加重期患者JAK/STAT通路蛋白及血气指标的影响[J].中南医学科学杂志,2021,49(4):464-467.[10]张三红,杜磊,邹珍.噻托溴铵对慢阻肺急性加重期肺部感染患者氧合指数与肺功能的影响及疗效观察[J].贵州医药,2018,42(6):690-692.[11]赵瑞芬,李霞,杨亚萍,等.噻托溴铵联合布地奈德/福莫特罗对慢性阻塞性肺疾病患者血管内皮功能及T淋巴细胞亚群的影响[J].心肺血管病杂志,2018,37(2):98-102.[12]夏文娟,王学中.布地奈德福莫特罗联合噻托溴铵对慢性阻塞性肺疾病急性加重期的临床疗效[J].安徽医学,2017,38(12):1572-1574.[13]王万征,安军.噻托溴铵对稳定期慢性阻塞性肺疾病患者临床疗效及相关血清标志物水平的影响[J].中国慢性病预防与控制,2017,25(5):358-360.[14]庄英鸿,尚东,巫瑞.噻托溴铵联合布地奈德福莫特罗吸入剂治疗稳定期慢性阻塞性肺疾病的临床疗效研究[J].药物评价研究,2017,40(11):1626-1630.[15]刘斌,冉献贵,邢青峰,等.噻托溴铵联合信必可都保治疗对慢阻肺患者肺功能和运动耐量及不良反应的影响[J].河北医学,2019,25(7):1108-1112.[16]李研,佟飞,米香.布地奈德福莫特罗粉吸入剂联合噻托溴铵粉吸入剂治疗ACOS的疗效及其对患者血清hs-CRP、EOS的影响[J].海南医学,2017,28(18):2997-3000.[17]许柳柳,朱洁晨,卞宏,等.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺疗效及对CRP、SaO2、PH水平影响[J].现代生物医学进展,2020,20(22):4369-4372.[18]余霓雯,王玉婷.噻托溴铵联合布地奈德福莫特罗对慢性阻塞性肺疾病的疗效及血清TGF-β、MMP-9、TIMP-1水平的影响[J].东南国防医药,2017,19(2):183-186.[19]王运.布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病的效果及其对患者肺功能和炎性递质的影响[J].新乡医学院学报,2017,34(10):932-935.[20]Yi G,Liang M,Li M,et al.A large lung gene expression study identifying IL1B as a novel player in airway inflammation in COPD airway epithelial cells[J].Inflammation Research,2018,67(6):539-551.

相似文献/References:

[1]黄朝宗.无创呼吸机对慢性阻塞性肺疾病急性加重患者治疗效果的影响[J].医学信息,2018,31(01):112.[doi:10.3969/j.issn.1006-1959.2018.01.042]
　HUANG Chao-zong.Effect of Noninvasive Ventilator on the Treatment of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(06):112.[doi:10.3969/j.issn.1006-1959.2018.01.042]
[2]温 蕾.复方异丙托溴铵常温雾化与加温雾化治疗 慢阻肺的护理效果分析[J].医学信息,2018,31(06):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
　WEN Lei.Analysis of Nursing Effect of Compound Ipratropium Bromide Nebulization at Room Temperature and Heating Atomization in Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(06):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
[3]王春艳,平玉卓,赵秀芹,等.协同护理干预对慢阻肺患者预后及自我护理能力的影响观察[J].医学信息,2018,31(13):181.[doi:10.3969/j.issn.1006-1959.2018.13.057]
　WANG Chun-yan,PING Yu-zhuo,ZHAO Xiu-qin,et al.Effect of Cooperative Nursing Intervention on Prognosis and Self-care Ability of Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(06):181.[doi:10.3969/j.issn.1006-1959.2018.13.057]
[4]鲁 婧,杜 君.肺心病左室舒张功能障碍发病机制的研究进展[J].医学信息,2019,32(04):54.[doi:10.3969/j.issn.1006-1959.2019.04.019]
　LU Jing,DU Jun.Advances in the Pathogenesis of Left Ventricular Diastolic Dysfunction in Pulmonary Heart Disease[J].Journal of Medical Information,2019,32(06):54.[doi:10.3969/j.issn.1006-1959.2019.04.019]
[5]周 笳,董丽霞.阿替普酶联合华法林治疗慢阻肺合并肺栓塞的有效性分析[J].医学信息,2019,32(05):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
　ZHOU Jia,DONG Li-xia.Efficacy Analysis of Alteplase Combined with Warfarin in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Embolism[J].Journal of Medical Information,2019,32(06):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
[6]刘伟娜.CD64感染指数、BODE指数与降钙素原在慢阻肺患者中的水平变化[J].医学信息,2019,32(06):125.[doi:10.3969/j.issn.1006-1959.2019.06.039]
　LIU Wei-na.Changes of CD64 Infection Index,BODE Index and Procalcitonin Levels in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(06):125.[doi:10.3969/j.issn.1006-1959.2019.06.039]
[7]钟红燕.盐酸氨溴索治疗慢阻肺合并肺部感染的临床效果[J].医学信息,2019,32(12):154.[doi:10.3969/j.issn.1006-1959.2019.12.051]
　ZHONG Hong-yan.Clinical Effect of Ambroxol Hydrochloride in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Infection[J].Journal of Medical Information,2019,32(06):154.[doi:10.3969/j.issn.1006-1959.2019.12.051]
[8]郑 新,张 颖.慢阻肺患者PSQI评分与NLR、PLR、CRP水平及急性加重频率的相关性[J].医学信息,2020,33(12):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
　ZHENG Xin,ZHANG Ying.Correlation of PSQI Score with NLR,PLR,CRP Level and Frequency of Acute Exacerbation in COPD Patients[J].Journal of Medical Information,2020,33(06):103.[doi:10.3969/j.issn.1006-1959.2020.12.031]
[9]田 芳.叙事护理对COPD患者负性情绪和呼吸症状群管理的效果[J].医学信息,2020,33(19):178.[doi:10.3969/j.issn.1006-1959.2020.19.058]
　TIAN Fang.The Effect of Narrative Nursing on the Management of Negative Emotion and Respiratory Symptoms in COPD Patients[J].Journal of Medical Information,2020,33(06):178.[doi:10.3969/j.issn.1006-1959.2020.19.058]
[10]李 婷.呼吸功能锻炼联合饮食护理干预对COPD生活质量的影响[J].医学信息,2021,34(01):188.[doi:10.3969/j.issn.1006-1959.2021.01.053]
　LI Ting.Effect of Respiratory Function Exercise Combined with Diet and Nursing Intervention on Life Quality of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2021,34(06):188.[doi:10.3969/j.issn.1006-1959.2021.01.053]
[11]王丽丽,石景瑜,张 敏.布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的临床疗效及药理学分析[J].医学信息,2022,35(23):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
　WANG Li-li,SHI Jing-yu,ZHANG Min.Clinical Efficacy and Pharmacological Analysis of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(06):136.[doi:10.3969/j.issn.1006-1959.2022.23.028]
[12]孙 茜,柴明思,齐秀芳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺的疗效及对CRP、SaO2、pH水平影响[J].医学信息,2023,36(10):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]
　SUN Qian,CHAI Ming-si,QI Xiu-fang.Efficacy of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP, SaO2 and pH Levels[J].Journal of Medical Information,2023,36(06):150.[doi:10.3969/j.issn.1006-1959.2023.10.033]

更新日期/Last Update: 1900-01-01